Path Economics’ Post

Must read The Evaluation of Pharmacy Strategic Plan in Past 2013-2016 and Forecasting of New Vision 2030 at Ministry of Health in Saudi Arabia https://lnkd.in/d7KJ98Hx #ResearchGate #2030Vision

Must read The Evaluation of Pharmacy Strategic Plan in Past 2013-2016 and Forecasting of New Vision 2030 at Ministry of Health in Saudi Arabia https://lnkd.in/dcn2byHp #ResearchGate #2030Vision

Seems like our government may be taking things for granted, ultimately the cost is to us, the tax payer. Many in society depend on medicine to keep them alive or improve their quality of life, they underpin healthcare in so many ways. Where’s the money going to come from if we don’t have these vital generic products on the market? For those that maybe don’t understand, a generic medicine is a copy of a medicine that held a patent, almost all low cost medicines start life like this! Imagine if there was only one manufacturer making paracetamol what do we think the cost would be? Certainly not 35p!

Our Purpose is pioneering access for patients – we do this by offering off-patent medicines, including biosimilar medicines.     Each year in November, we support the annual #GlobalBiosimilarsWeek, organized by the IGBA - International Generic and Biosimilar medicines Association, to raise awareness about the value of biosimilars in providing patient access to treatment options that allow them to lead healthier lives.       This year is no different. From November 11th-15th we are encouraging all stakeholders - patients, healthcare professionals and organizations around the world to share their perspectives as we explore the urgent need for ‘Advancing Access to Biosimilars.’    On November 8th at 11:00 CET, Sandoz and the Slovenian Ministrstvo za gospodarstvo, turizem in šport / Ministry of the Economy, Tourism and Sport are hosting a panel to discuss how we strengthen European biomanufacturing in an effort to meet the growing demand for biosimilars.     To learn more or register to attend click here:   https://lnkd.in/ehkQFK-U

Today, on World Asthma Day 2024, AKS Khan Pharmaceuticals Limited stand united in the commitment to asthma management with quality medicine and quality care to breathe easier. #WorldAsthmaDay #AKSPharmacy #AKSHealthcare"

The global healthcare market is expected to develop rapidly over the next decade with innovation in medicines and therapies, advances in precision medicine, genomics and the wide range of treatment modalities available. The transformative impact of the Saudi Arabian initiatives is improving healthcare infrastructure, research, and economic growth. KSA is driving significant changes in the country's healthcare sector, aligning with the goals of Vision 2030. Companies like PIF PIF are acting as a catalyst, aiming to enable the domestic healthcare eco-system whilst creating significant opportunities for the private sector: 1) Implementing healthcare models that prioritize health and are driven by primary care providers.  2) Promote self-governance and responsibility while guaranteeing openness and cooperation through standardized methods of transforming into corporations and integrating different entities. 3) Attain a superior and smoothly coordinated experience throughout different degrees of healthcare and institutions.  4) Integrate population health strategies and maximize the allocation of resources in service delivery.  5) Establish uniform assessment criteria for measuring performance and results across different service providers and geographic locations.  6) Create a learning health system that guarantees ongoing enhancement. 7) Integrating diverse initiatives across governance, integrated care, public health, supply chain, digital infrastructure, R&D, and collaboration with private and non-profit sectors, enhancing investment appeal in healthcare transformation. These initiatives are reshaping Saudi Arabia's healthcare landscape, contributing to Vision 2030 goals of economic diversification and improved quality of life. With continued investment and innovation, Saudi Arabia will emerge as a global leader in modern healthcare, ensuring the well-being and prosperity of its citizens #globalhealthcare #innovationinhealthcare #precisionmedicine #genomics #healthcareinfrastructure #saudihealthcare #vision2030 #healthcaretransformation #pif #healthcareecosystem #primarycare #populationhealth #healthcarequality #economicgrowth #saudiinnovation #healthcareinvestment #healthcareleadership https://lnkd.in/dYQUvK9n

Asthma and COPD pose significant challenges for individuals living with these conditions in addition to the burden on healthcare budget, Addressing these challenges requires a comprehensive approach that includes proper medication management, lifestyle modifications, environmental control, emotional support, and regular medical supervision. Moreover, raising awareness about these conditions and promoting respiratory health is crucial for supporting individuals living with asthma and COPD. Let’s work together to overcome these challenges, improve patients quality of life and eliminate COPD as one of the leading causes of death.

In December 2023, the European Medicines Agency (EMA) recognised the vital importance of plasma- derived medicines by listing almost all of them on the European Union's first Critical Medicines List. During #IPAW2024, let's advocate for policies that support consistent access to critical treatment such as plasma-derived therapies. Write to an MEP about this issue by downloading a templated letter at www.plasmaweek.org.

As vendors to Novartis Saudi Arabia | نوفارتس السعودية and IQVIA Middle East and Africa, we are happy to share the findings of our #RWE study with the medical community. This study was led by Dr. Ibrahim Al-Homod, MD,FACP, consultant internal medicine, esteemed Rheumatologist and Chairman of the postgraduate department at King Fahad Medical City - KFMC. We determined the “treatment retention rate” to check the percentage of patients who continued to use the drug over 6 and 12 months. The percentage of treatment retention after 6 months was 100%. Considering the patients who started secukinumab 12 months or more prior to the study cutoff date (December 2022), the 12-month retention rate was 85%. DAPSA score showed a statistically significant decrease among those who received secukinumab alone by approximately 20.9 and 21.4 (p values < 0.001 for each) compared to 23.7 and 25.9 in combination with MTX (p-value = 0.012 & 0.006, respectively) after 6 and 12 months of treatment, respectively, compared to the baseline. read more (link in the comments)!

Clinical Trials in Saudi Arabia: An Insight from PDC-CRO Discover how PDC-CRO is transforming the landscape of clinical trials in Saudi Arabia. Learn about their innovative direct-to-biotech strategy, their alignment of financial investment and operational strategy, and their future plans in our latest article. #ClinicalTrials #HealthcareInnovation #PDC-CRO 🌍🔬👩🔬. Read more here. https://lnkd.in/dpHdDAk5